Cargando…

Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment

Detalles Bibliográficos
Autores principales:	Cheng, Binbin, Wang, Wei, Liu, Ting, Cao, Hao, Pan, Wei, Xiao, Yao, Liu, Shuwen, Chen, Jianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974934/ https://www.ncbi.nlm.nih.gov/pubmed/36854661 http://dx.doi.org/10.1038/s41392-022-01292-5

Ejemplares similares

CXCL10 Acts as a Bifunctional Antimicrobial Molecule against Bacillus anthracis
por: Margulieux, Katie R., et al.
Publicado: (2016)

Targeting Ribonucleases with Small Molecules and Bifunctional Molecules
por: Borgelt, Lydia, et al.
Publicado: (2023)

Structural Analysis of a Novel Small Molecule Ligand Bound to the CXCL12 Chemokine
por: Smith, Emmanuel W., et al.
Publicado: (2014)

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer’s disease
por: Liang, Meihao, et al.
Publicado: (2022)

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Dual role for CXCL12 signaling in semilunar valve development
por: Ridge, Liam A., et al.
Publicado: (2021)

Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation
por: Gibson, William J., et al.
Publicado: (2023)

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate
por: Xiao, Dian, et al.
Publicado: (2021)

CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
por: Mezzapelle, Rosanna, et al.
Publicado: (2022)

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
por: Wu, Zhen-Hua, et al.
Publicado: (2022)

Small-Molecule PROTACs for Cancer Immunotherapy
por: Liu, Zefan, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Bifunctional Small Molecules Enhance Neutrophil Activities Against Aspergillus fumigatus in vivo and in vitro
por: Jones, Caroline N., et al.
Publicado: (2019)

Mesenchymal stem cells over-expressing cxcl12 enhance the radioresistance of the small intestine
por: Chang, Pengyu, et al.
Publicado: (2018)

Low content Ru-incorporated Pd nanowires for bifunctional electrocatalysis
por: Kweon, Yongdeog, et al.
Publicado: (2021)

Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-β Species in Alzheimer's Disease
por: Braymer, Joseph J., et al.
Publicado: (2010)

cxcl12a plays an essential role in pharyngeal cartilage development
por: Wei, Zhaohui, et al.
Publicado: (2023)

Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients
por: Najmaddini, Hamid, et al.
Publicado: (2014)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
por: Goltz, Diane, et al.
Publicado: (2016)

Small-Molecule Targets in Tumor Immunotherapy
por: Zhu, Hui-Fang, et al.
Publicado: (2018)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

CXCR7 Functions as a Scavenger for CXCL12 and CXCL11
por: Naumann, Ulrike, et al.
Publicado: (2010)

Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells
por: Koch, Christian, et al.
Publicado: (2022)

Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3
por: Nedjai, Belinda, et al.
Publicado: (2012)

ANTIGEN RECOGNITION AND THE IMMUNE RESPONSE : HUMORAL AND CELLULAR IMMUNE RESPONSES TO SMALL MONO- AND BIFUNCTIONAL ANTIGEN MOLECULES
por: Alkan, Sefik S., et al.
Publicado: (1972)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Sonochemical Reaction of Bifunctional Molecules on Silicon (111) Hydride Surface
por: Zida, Serge Ismael, et al.
Publicado: (2021)

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
por: Suarez-Carmona, Meggy, et al.
Publicado: (2021)

Correction: Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells
por: Koch, Christian, et al.
Publicado: (2023)

The Role of CXCL12 Axis in Lung Metastasis of Colorectal Cancer
por: Wang, Meng, et al.
Publicado: (2018)

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
por: Zhong, Yanwen, et al.
Publicado: (2019)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
por: Dextras, Christopher, et al.
Publicado: (2020)

Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12
por: Xu, Yanjun, et al.
Publicado: (2023)

Is the Triggering of PD-L1 Dimerization a Potential Mechanism for Food-Derived Small Molecules in Cancer Immunotherapy? A Study by Molecular Dynamics
por: Wu, Xiaoyan, et al.
Publicado: (2023)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Seminal Levels of Pro-inflammatory (CXCL1, CXCL9, CXCL10) and Homeostatic (CXCL12) Chemokines in Men With Asymptomatic Chlamydia trachomatis Infection
por: Hakimi, Hamid, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i3tms5t6hretmqrotrdr2dm50k